Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 19 | 2025 | 3744 | 1.430 |
Why?
|
| Liver Neoplasms | 12 | 2023 | 1368 | 1.370 |
Why?
|
| Carcinoma, Hepatocellular | 11 | 2023 | 977 | 1.240 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2016 | 18 | 0.980 |
Why?
|
| Contrast Media | 6 | 2023 | 473 | 0.950 |
Why?
|
| Epinephrine | 2 | 2016 | 148 | 0.910 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2023 | 2058 | 0.890 |
Why?
|
| Drug Hypersensitivity | 2 | 2016 | 99 | 0.880 |
Why?
|
| Ultrasonography | 5 | 2021 | 943 | 0.710 |
Why?
|
| Liver Diseases | 4 | 2026 | 378 | 0.660 |
Why?
|
| Adnexal Diseases | 2 | 2017 | 22 | 0.620 |
Why?
|
| Urolithiasis | 2 | 2016 | 9 | 0.620 |
Why?
|
| Radiosurgery | 5 | 2021 | 148 | 0.610 |
Why?
|
| Uterine Neoplasms | 2 | 2018 | 100 | 0.600 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2019 | 6 | 0.590 |
Why?
|
| Radiology | 2 | 2021 | 119 | 0.590 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 421 | 0.580 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2018 | 23 | 0.540 |
Why?
|
| Radiologists | 1 | 2018 | 52 | 0.540 |
Why?
|
| Elasticity Imaging Techniques | 3 | 2026 | 157 | 0.500 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 205 | 0.490 |
Why?
|
| Incidental Findings | 1 | 2017 | 122 | 0.480 |
Why?
|
| Urinary Tract | 1 | 2016 | 54 | 0.480 |
Why?
|
| Perfusion Imaging | 1 | 2016 | 11 | 0.480 |
Why?
|
| Radiology Information Systems | 3 | 2021 | 27 | 0.470 |
Why?
|
| Kidney Calculi | 1 | 2016 | 39 | 0.450 |
Why?
|
| Artifacts | 1 | 2016 | 99 | 0.440 |
Why?
|
| Radiation Injuries | 1 | 2016 | 141 | 0.430 |
Why?
|
| Calcinosis | 1 | 2016 | 178 | 0.420 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 250 | 0.410 |
Why?
|
| Liver | 5 | 2026 | 1788 | 0.410 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 304 | 0.400 |
Why?
|
| Clinical Competence | 2 | 2018 | 1042 | 0.350 |
Why?
|
| Abdomen | 2 | 2024 | 125 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1267 | 0.320 |
Why?
|
| Diagnosis, Differential | 5 | 2018 | 1872 | 0.290 |
Why?
|
| Humans | 33 | 2026 | 130154 | 0.240 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1306 | 0.240 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2024 | 229 | 0.220 |
Why?
|
| Brain | 1 | 2016 | 3146 | 0.200 |
Why?
|
| Spleen | 1 | 2024 | 258 | 0.200 |
Why?
|
| Middle Aged | 16 | 2026 | 28331 | 0.200 |
Why?
|
| Retrospective Studies | 13 | 2026 | 17554 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 370 | 0.180 |
Why?
|
| Lymphedema | 1 | 2022 | 19 | 0.180 |
Why?
|
| Lymphatic Diseases | 1 | 2022 | 28 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 588 | 0.170 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 10 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2021 | 6403 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2021 | 229 | 0.160 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2020 | 23 | 0.160 |
Why?
|
| Algorithms | 3 | 2021 | 1661 | 0.150 |
Why?
|
| Female | 15 | 2026 | 70285 | 0.150 |
Why?
|
| Reproducibility of Results | 5 | 2026 | 2896 | 0.140 |
Why?
|
| Aged | 9 | 2026 | 20833 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 1406 | 0.140 |
Why?
|
| Adenomyosis | 1 | 2018 | 10 | 0.140 |
Why?
|
| Patients | 1 | 2019 | 122 | 0.140 |
Why?
|
| Liver Cirrhosis | 1 | 2025 | 902 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2018 | 71 | 0.130 |
Why?
|
| Adnexa Uteri | 1 | 2017 | 6 | 0.130 |
Why?
|
| Adult | 9 | 2026 | 31042 | 0.120 |
Why?
|
| Drug Administration Routes | 1 | 2016 | 29 | 0.120 |
Why?
|
| Laryngeal Diseases | 1 | 2016 | 28 | 0.120 |
Why?
|
| Peritoneal Diseases | 1 | 2016 | 10 | 0.120 |
Why?
|
| Cerebral Blood Volume | 1 | 2016 | 6 | 0.120 |
Why?
|
| Fibroma | 1 | 2016 | 29 | 0.120 |
Why?
|
| Young Adult | 4 | 2024 | 9987 | 0.120 |
Why?
|
| Patient Simulation | 1 | 2016 | 40 | 0.120 |
Why?
|
| Biopsy | 2 | 2018 | 1237 | 0.120 |
Why?
|
| Spinal Diseases | 1 | 2016 | 46 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2017 | 108 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 170 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2016 | 67 | 0.110 |
Why?
|
| Frontal Lobe | 1 | 2016 | 110 | 0.110 |
Why?
|
| Necrosis | 1 | 2016 | 193 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 2016 | 103 | 0.110 |
Why?
|
| Edema | 1 | 2016 | 129 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 38 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 283 | 0.110 |
Why?
|
| Male | 12 | 2026 | 64397 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1278 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 208 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12843 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 402 | 0.100 |
Why?
|
| White Matter | 1 | 2016 | 213 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2023 | 2079 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1606 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 6768 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 342 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 551 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2021 | 1218 | 0.080 |
Why?
|
| Adolescent | 4 | 2024 | 20802 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5161 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2016 | 707 | 0.080 |
Why?
|
| Kidney | 1 | 2016 | 1279 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 116 | 0.070 |
Why?
|
| Molecular Epidemiology | 1 | 2008 | 139 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 478 | 0.050 |
Why?
|
| Bacteremia | 1 | 2008 | 430 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 563 | 0.050 |
Why?
|
| Lymphography | 1 | 2022 | 9 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2022 | 18 | 0.050 |
Why?
|
| Risk Factors | 1 | 2016 | 10953 | 0.040 |
Why?
|
| Personnel Selection | 1 | 2021 | 79 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 348 | 0.040 |
Why?
|
| Digital Rectal Examination | 1 | 2018 | 5 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 325 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2021 | 810 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2018 | 222 | 0.030 |
Why?
|
| Vagina | 1 | 2018 | 207 | 0.030 |
Why?
|
| Uterine Hemorrhage | 1 | 2016 | 41 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 70 | 0.030 |
Why?
|
| Prostate | 1 | 2018 | 402 | 0.030 |
Why?
|
| Breast | 1 | 2016 | 213 | 0.030 |
Why?
|
| United States | 2 | 2021 | 11885 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 790 | 0.030 |
Why?
|
| Uterus | 1 | 2018 | 545 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1440 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1157 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3680 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1374 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4032 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 3407 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5042 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 15009 | 0.020 |
Why?
|
| Vancomycin Resistance | 1 | 2008 | 22 | 0.020 |
Why?
|
| Michigan | 1 | 2008 | 47 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2008 | 89 | 0.020 |
Why?
|
| Geography | 1 | 2008 | 114 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2008 | 97 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 106 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 412 | 0.020 |
Why?
|
| Virulence Factors | 1 | 2008 | 180 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2008 | 479 | 0.020 |
Why?
|
| Urban Population | 1 | 2008 | 282 | 0.010 |
Why?
|
| Community-Acquired Infections | 1 | 2008 | 252 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 851 | 0.010 |
Why?
|
| Cross Infection | 1 | 2008 | 333 | 0.010 |
Why?
|
| Child | 1 | 2024 | 26181 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 944 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 2588 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 2577 | 0.010 |
Why?
|